CD160 and B-cell chronic lymphocytic leukemia: Future studies should be conducted to evaluate the targeting of CD160 by monoclonal antibodies in CLL, the potential effect of such agents on the reactivation of NK cells, and their induction of antibody-dependent cellular cytotoxicity (ADCC).